Amino Acid, Peptide, or Protein – Page 4

CDC Updates COVID-19 and Chickenpox Vaccine Guidance Based on ACIP Recommendations

3 weeks ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), Chickenpox, Chickenpox Vaccine, COVID19 (disease), Febrile Convulsions, Immunization Schedule, individual-based decision-making, measles, mumps, rubella, varicella vaccine, Vaccines

CDC; COVID-19 vaccine; chickenpox vaccine; ACIP; individual-based decision-making; MMRV; varicella; immunization schedule; febrile seizure

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

3 weeks ago talkbio0Tagged ADC, AstraZeneca, Clinical Trials, Daiichi, Datopotamab deruxtecan, Datroway, Immunotherapy, Overall Survival, Pharmacotherapy, Phase 3 trial, Sankyo, therapeutic autologous dendritic cells, Triple Negative Breast Neoplasms, TROPION-Breast02

Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

3 weeks ago talkbio0Tagged ALK gene, biomarker testing, Epidermal Growth Factor Receptor, Liquid Biopsy, next-generation sequencing, Non-Small Cell Lung Carcinoma, Overall Survival, PD-L1, Precision Medicine, Real-world

NSCLC; biomarker testing; overall survival; PD-L1; EGFR; ALK; next-generation sequencing; liquid biopsy; precision medicine; real-world data

Skye Bioscience’s Nimacimab Fails Mid-Stage Obesity Trial, Stock Plummets

3 weeks ago talkbio0Tagged CB1 inhibitor, Clinical Setback, Nimacimab, Obesity Trial, Weight-Loss Agents

nimacimab; CB1 inhibitor; obesity trial; clinical setback; weight loss drug

Recent Law Expands Orphan Drug Protections, Shielding Blockbusters from Medicare Price Negotiations

3 weeks ago talkbio0Tagged Big Beautiful Bill, Congress (U.S. Legislature), Drug Industry, drug price, Inflation Reduction Act, Keytruda, Medicare, negotiation, OBBBA, Opdivo, orphan drug exclusion

orphan drug exclusion; Medicare negotiation; One Big Beautiful Bill; Keytruda; Opdivo; Inflation Reduction Act; OBBBA; drug pricing; Congress; pharmaceutical industry

Vaxcyte Strikes up to $1B Fill-Finish Manufacturing Deal with Thermo Fisher at North Carolina Facility

3 weeks ago talkbio0Tagged biomanufacturing, commercial supply chain, Manufacturing, North Carolina, PCVs, pneumococcal conjugate vaccines, production, Thermo Fisher Scientific, United States, Vaccines, VAX-24, VAX-31, Vaxcyte

Vaxcyte; Thermo Fisher Scientific; fill-finish manufacturing; North Carolina; pneumococcal conjugate vaccines; PCVs; VAX-31; VAX-24; commercial supply chain; biomanufacturing; U.S. vaccine production; $1 billion deal

Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data

3 weeks ago talkbio0Tagged amgen, Approved, Cardiovascular Diseases, Cardiovascular event, Cerebrovascular accident, LDL-C, Myocardial Infarction, PCSK9 inhibitor, Primary Prevention, Repatha, United States Food and Drug Administration, VESALIUS-CV trial

Amgen; Repatha; VESALIUS-CV trial; primary prevention; cardiovascular disease; PCSK9 inhibitor; LDL-C; FDA approval; major adverse cardiovascular events; heart attack; stroke

Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

3 weeks ago talkbio0Tagged Antibodies, Biosciences, Cartography, CBI-1214, Cervical Atlas, Colorectal Carcinoma, Neoplasms, Pfizer Ventures, Platform, Series B funding, summit, T-Cell engager

Cartography Biosciences; Series B Funding; Pfizer Ventures; CBI-1214; T-cell engager; colorectal cancer (CRC); ATLAS platform; SUMMIT platform; antibody therapeutics; oncology

Amgen’s Repatha Cholesterol-Lowering Shot Poised for Sales Boost After Landmark CV Prevention Trial Success

4 weeks ago talkbio0Tagged amgen, cardiovascular trial, cholesterol-lowering, Heart Diseases, LDL Cholesterol Lipoproteins, PCSK9 inhibitor, Primary Prevention, Repatha, Sales - occupational activity, VESALIUS-CV

Amgen; Repatha; cholesterol-lowering; PCSK9 inhibitor; cardiovascular trial; VESALIUS-CV; primary prevention; heart disease; sales; LDL cholesterol

AnaptysBio Announces Strategic Business Split to Create Two Public Companies, Sharpening Asset Focus

4 weeks ago talkbio0Tagged AnaptysBio, asset, biopharmaceutical development, business split, Immunology, Imsidolimab, Jemperli, public companies, restructuring, royalty management

AnaptysBio; business split; royalty management; biopharmaceutical development; Jemperli; imsidolimab; public companies; immunology treatments; asset value; restructuring